VTRS vs. SRPT, UTHR, RDY, BMRN, BGNE, CTLT, ROIV, ELAN, LEGN, and VKTX
Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical preparations" industry.
Viatris (NASDAQ:VTRS) and Sarepta Therapeutics (NASDAQ:SRPT) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
Sarepta Therapeutics received 1405 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 75.41% of users gave Sarepta Therapeutics an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Sarepta Therapeutics has a net margin of 1.20% compared to Viatris' net margin of -0.37%. Viatris' return on equity of 16.63% beat Sarepta Therapeutics' return on equity.
Viatris has higher revenue and earnings than Sarepta Therapeutics. Viatris is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viatris has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
79.9% of Viatris shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Sarepta Therapeutics had 11 more articles in the media than Viatris. MarketBeat recorded 14 mentions for Sarepta Therapeutics and 3 mentions for Viatris. Viatris' average media sentiment score of 0.98 beat Sarepta Therapeutics' score of 0.89 indicating that Viatris is being referred to more favorably in the media.
Viatris presently has a consensus price target of $11.00, indicating a potential upside of 0.18%. Sarepta Therapeutics has a consensus price target of $163.94, indicating a potential upside of 24.78%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than Viatris.
Summary
Sarepta Therapeutics beats Viatris on 12 of the 18 factors compared between the two stocks.
Get Viatris News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
